Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.8K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

1.5K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.5K
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

572
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
572
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

3.7K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
3.7K
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

826
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
826
Cholecystitis01:20

Cholecystitis

32
Cholecystitis is inflammation of the gallbladder, most commonly caused by obstruction of the cystic duct. This blockage prevents bile from draining, leading to gallbladder distension, inflammation, and potentially serious complications. This condition may present acutely or chronically and can happen with or without gallstones.EtiologyAbout 95% of cholecystitis cases are calculous, caused by gallstones blocking the cystic duct, leading to bile accumulation and inflammation of the gallbladder...
32

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of mental fatigue on the performance of Australian football specific skills amongst amateur athletes.

Journal of science and medicine in sport·2021
Same author

Computational fluid dynamics modeling of <i>Bacillus anthracis</i> spore deposition in rabbit and human respiratory airways.

Journal of aerosol science·2020
Same author

Author response to: Defining true impact of anastomotic leaks after oesophagogastric cancer surgery.

The British journal of surgery·2020
Same author

Impact of postoperative complications on disease recurrence and long-term survival following oesophagogastric cancer resection.

The British journal of surgery·2019
Same author

Cortical motor threshold determination in dogs.

Research in veterinary science·2019
Same author

A Change of Government and Its Effect on the NHS Hospital Outpatient Service.

Journal of the Royal College of Physicians of London·2019

Related Experiment Video

Updated: May 5, 2026

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

56.6K

Ursodeoxycholic acid therapy and biliary lipids--a dose-response study

M C Bateson, P E Ross, J Murison

    Gut
    |April 1, 1980
    PubMed
    Summary

    Ursodeoxycholic acid therapy significantly alters bile composition in patients with gallstones. Higher doses (750-1000 mg) effectively reduced bile cholesterol saturation, aiding in gallstone dissolution.

    More Related Videos

    Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport
    08:42

    Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport

    Published on: November 27, 2016

    10.5K
    Ileectomy-induced Bile Overaccumulation in Mouse Intestine
    06:55

    Ileectomy-induced Bile Overaccumulation in Mouse Intestine

    Published on: August 21, 2017

    8.9K

    Related Experiment Videos

    Last Updated: May 5, 2026

    Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
    08:56

    Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

    Published on: February 10, 2015

    56.6K
    Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport
    08:42

    Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport

    Published on: November 27, 2016

    10.5K
    Ileectomy-induced Bile Overaccumulation in Mouse Intestine
    06:55

    Ileectomy-induced Bile Overaccumulation in Mouse Intestine

    Published on: August 21, 2017

    8.9K

    Area of Science:

    • Hepatology
    • Gastroenterology
    • Bile Acid Metabolism

    Background:

    • Gallstones are a common condition often treated with bile acid therapy.
    • Ursodeoxycholic acid (UDCA) is a primary medical treatment for radiolucent gallstones.
    • Understanding UDCA's effects on biliary lipids is crucial for optimizing treatment.

    Purpose of the Study:

    • To investigate the dose-dependent effects of ursodeoxycholic acid on biliary lipid composition.
    • To assess the impact of UDCA on cholesterol saturation in patients with gallstones.

    Main Methods:

    • A study involving 24 patients with radiolucent gallbladder stones.
    • Administration of four different doses of ursodeoxycholic acid (250, 500, 750, 1000 mg daily).
    • Analysis of biliary lipid profiles and cholesterol saturation before and after treatment.

    Main Results:

    • All UDCA doses increased the proportion of ursodeoxycholic acid in bile, with maximal effects at 750 and 1000 mg.
    • Bile cholesterol content significantly decreased, most notably with the 1000 mg dose (P < 0.01).
    • Significant improvement in biliary cholesterol saturation was observed only at 750 and 1000 mg daily doses.

    Conclusions:

    • Ursodeoxycholic acid effectively modifies bile acid composition and reduces cholesterol saturation in patients with gallstones.
    • Higher doses of ursodeoxycholic acid (750-1000 mg) are more effective in improving cholesterol saturation, suggesting a dose-response relationship.
    • These findings support the use of optimized ursodeoxycholic acid dosages for medical management of gallstones.